Dopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion

被引:30
|
作者
Margolis, Elyssa B. [1 ]
Karkhanis, Anushree N. [2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, Alcohol & Addict Res Grp, 675 Nelson Rising Lane,Box 0444, San Francisco, CA 94143 USA
[2] SUNY Binghamton, Dept Psychol, Dev Exposure Alcohol Res Ctr, Ctr Dev & Behav Neurosci, 4400 Vestal Pkwy East, Binghamton, NY 13902 USA
基金
美国国家卫生研究院;
关键词
VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS SHELL; PLACE PREFERENCE PARADIGM; SOCIAL DEFEAT STRESS; SELECTIVE ACTIVATION; CATECHOLAMINE INNERVATION; PRESYNAPTIC INHIBITION; BASOLATERAL AMYGDALA; LATERAL HABENULA; MEASURING REWARD;
D O I
10.1016/j.neuint.2019.104504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neural circuits that enable an organism to protect itself by promoting escape from immediate threat and avoidance of future injury are conceptualized to carry an "aversive" signal. One of the key molecular elements of these circuits is the kappa opioid receptor (KOR) and its endogenous peptide agonist, dynorphin. In many cases, the aversive response to an experimental manipulation can be eliminated by selective blockade of KOR function, indicating its necessity in transmitting this signal. The dopamine system, through its contributions to reinforcement learning, is also involved in processing of aversive stimuli, and KOR control of dopamine in the context of aversive behavioral states has been intensely studied. In this review, we have discussed the multiple ways in which the KORs regulate dopamine dynamics with a central focus on dopamine neurons and projections from the ventral tegmental area. At the neuronal level, KOR agonists inhibit dopamine neurons both in the somatodendritic region as well as at terminal release sites, through various signaling pathways and ion channels, and these effects are specific to different synaptic sites. While the dominant hypotheses are that aversive states are driven by decreases in dopamine and increases in dynorphin, reported exceptions to these patterns indicate these ideas require refinement. This is critical given that KOR is being considered as a target for development of new therapeutics for anxiety, depression, pain, and other psychiatric disorders.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Dopaminergic modulation of kappa opioid-mediated ultrasonic vocalization, antinociception, and locomotor activity in the preweanling rat
    Nazarian, A
    Rodarte-Freeman, AL
    McDougall, SA
    BEHAVIORAL NEUROSCIENCE, 1999, 113 (04) : 816 - 825
  • [22] KAPPA-OPIOID RECEPTOR-MEDIATED THERMONOCICEPTIVE MECHANISMS IN STREPTOZOTOCIN DIABETES
    BANSINATH, M
    RAMABADRAN, K
    TURNDORF, H
    PUIG, MM
    PHYSIOLOGY & BEHAVIOR, 1991, 49 (04) : 729 - 733
  • [23] The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated
    Ross, FB
    Smith, MT
    PAIN, 1997, 73 (02) : 151 - 157
  • [24] MU-OPIOID AND KAPPA-OPIOID RECEPTOR-MEDIATED OPIOID EFFECTS ON SOCIAL PLAY IN JUVENILE RATS
    VANDERSCHUREN, LJMJ
    NIESINK, RJM
    SPRUIJT, BM
    VANREE, JM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 276 (03) : 257 - 266
  • [25] OPIOID RECEPTORS IN MIDBRAIN DOPAMINERGIC REGIONS OF THE RAT .2. KAPPA-RECEPTOR AND DELTA-RECEPTOR AUTORADIOGRAPHY
    SPECIALE, SG
    MANAYE, KF
    SADEQ, M
    GERMAN, DC
    JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1993, 91 (01) : 53 - 66
  • [26] A review of the kappa opioid receptor system in opioid use
    Cayir, Salih
    Zhornitsky, Simon
    Barzegary, Alireza
    Sotomayor-Carreno, Esteban
    Sarfo-Ansah, Wonder
    Funaro, Melissa C.
    Matuskey, David
    Angarita, Gustavo
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2024, 162
  • [27] Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action
    Reichard, Kathryn L.
    Newton, Keionna A.
    Rivera, Zeena M. G.
    de Menezes, Paulo M. Sotero
    Schattauer, Selena S.
    Land, Benjamin B.
    Chavkin, Charles
    MOLECULAR PHARMACOLOGY, 2020, 98 (05) : 548 - 558
  • [28] Novel opioid peptides as kappa opioid receptor antagonists
    Aldrich, JV
    Wan, Q
    Murray, TF
    PEPTIDES FOR THE NEW MILLENNIUM, 2000, : 616 - 618
  • [29] Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor
    Pan, ZZ
    Tershner, SA
    Fields, HL
    NATURE, 1997, 389 (6649) : 382 - 385
  • [30] Kappa-opioid receptor ligands
    Husbands, SM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (12) : 1725 - 1741